Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03626545
Title	Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)
Acronym	CANOPY-2
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	lung non-small cell carcinoma
Therapies	Canakinumab + Docetaxel Docetaxel
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NLD \| LBN \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG